EP1904045A1 - Utilisation de la 4-(3,4-dichloro-phenyl)-1,2,3,4-tetrahydro-naphtalen-1-ylamine pour le traitement du cancer - Google Patents
Utilisation de la 4-(3,4-dichloro-phenyl)-1,2,3,4-tetrahydro-naphtalen-1-ylamine pour le traitement du cancerInfo
- Publication number
- EP1904045A1 EP1904045A1 EP06777730A EP06777730A EP1904045A1 EP 1904045 A1 EP1904045 A1 EP 1904045A1 EP 06777730 A EP06777730 A EP 06777730A EP 06777730 A EP06777730 A EP 06777730A EP 1904045 A1 EP1904045 A1 EP 1904045A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- cancer
- ylamine
- tetrahydro
- naphthalen
- dichloro
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
Definitions
- the present invention relates to the use of 4- (3,4-dichlorophenyl) -1,2,3,4-tetrahydro-naphthalen-1-ylamine or one of its enantiomers or any combination thereof its enantiomers for the preparation of pharmaceutical compositions for the treatment of cancer, as well as the treatment and prevention of metastases.
- the annual number of new cancer cases has increased significantly over the last twenty years.
- the treatment of cancer is therefore a real public health problem. Whatever the type of cancer, treatment with chemotherapy is generally recommended, if only in adjuvant treatment. There is therefore a continuing need to develop new molecules for chemotherapy.
- the inventors have studied 4- (3,4-dichloro-phenyl) -1,2,3,4-tetrahydro-naphthalen-1-ylamine and its enantiomers or any combination of its enantiomers, and have shown that these compounds possess a antiproliferative activity on many types of tumor cells, and that they can be used in the prevention or treatment of cancers.
- the present invention therefore relates to the use of 4- (3,4-dichlorophenyl) -1,2,3,4-tetrahydro-naphthalen-1-ylamine or one of its enantiomers selected from ((1S, 4S) 4- (3,4-Dichloro-phenyl) -1,2,3,4-tetrahydro-naphthalen-1-ylamine, (1S, 4R) 4- (3,4-dichlorophenyl) -1, 2,3,4-tetrahydro-naphthalen-1-ylamine (1R, 4S) 4- (3,4-dichloro-phenyl) -1,2,3,4-tetrahydro-naphthalen-1-ylamine and (1R , 4R) 4- (3,4-dichloro-phenyl) -1,2,3,4-tetrahydro-naphthalen-1-ylamine) or any combination of its enantiomers for the preparation of a pharmaceutical composition for the treatment cancer and the treatment
- the compounds according to the present invention possess a remarkable ability to destroy tumor cells.
- the results were particularly spectacular with respect to the ability of these products to affect tumor cells from many different types of cancer.
- said cancer or said metastases are derived from a cancer selected from the group consisting of prostate cancer, osteosarcomas, lung cancer, non-small cell lung cancer, breast cancer, endometrial cancer or colon cancer, chronic or acute leukemia, solid tumors of the child, lymphocytic lymphoma, pancreatic cancer, skin cancer, cutaneous or intraocular melanoma, cancer of the head and neck, uterine cancer, ovarian cancer, gynecological tumors, Hodgkin's disease, bone cancer, rectal cancer, cancer of the anal region, cancer of the uterus stomach, esophageal cancer, small bowel cancer, endocrine system cancer, soft tissue sarcomas, urethral cancer, penile cancer, bladder cancer, cancer of the kidney, cancer of the ureter, pediatric malignancies and of the central nervous system, particularly brain tumors.
- said cancer or said metastases are derived from breast cancer.
- said cancer or said metastases are derived from breast
- Another aspect of the invention thus relates to the use of 4- (3,4-dichloro-phenyl) -1,2,3,4-tetrahydro-naphthalen-1-ylamine or one of its enantiomers or any combination of its enantiomers and at least one alkaloid for the preparation of a pharmaceutical composition for the treatment of cancer, as well as for the treatment and prevention of metastases.
- the alkaloid is a vinca alkaloid. More preferably, the vinca alkaloid is selected from the group consisting of: vinblastine, vincristine, vindesine, and vinorelbine, preferably vincristine and / or vinblastine.
- alkaloid of vinca is intended to mean, according to the present invention, the alkaloids of the periwinkle, Vinca rosea, and their derivatives obtained by chemical modification. They target tubulin achromatic spindle mitosis which they inhibit the polymerization. This tubulin also constituting the nerve fibers, the alkaloids of vinca have a nerve toxicity, especially sensitive, and induce a depressive tendency.
- Another aspect of the invention relates to products comprising
- the alkaloid chosen is a vinca alkaloid. More preferably, the vinca alkaloid is selected from the group consisting of: vinblastine, vincristine, vindesine, and vinorelbine, preferably vincristine and / or vinblastine.
- compositions and / or combination products according to the present invention can be administered orally, intravenously, enterally, parenterally, intramuscularly, intranasally, subcutaneously sublingually or topically.
- oral or default injectables in particular for the treatment of tumors.
- the inventors have demonstrated that the products of the present invention can be orally effective, unlike many anti-tumor products now available to patients (Goodman &Gilman's Pharmacological Basis of Therapeutics, Mc Graw HiIl Editor). ).
- Daily dosages should take into account the condition of the patient but also the treated cancer, its stage and its progression.
- Figure 1 Study of the synergistic effect of combinations of 4- (3,4-dichlorophenyl) -1,2,3,4-tetrahydro-naphthalen-1-ylamine cis and vincristine on inhibition of proliferation U937 leukemia-like cells
- Figure 2 Study of the synergistic effect of combinations of 4- (3,4-dichlorophenyl) -1,2,3,4-tetrahydro-naphthalen-1-ylamine cis and vinblastine on inhibition of proliferation U937 leukemia-like cells
- Figure 3 Study of the synergistic effect of combinations of 4- (3,4-dichlorophenyl) -1,2,3,4-tetrahydro-naphthalen-1-ylamine cis and vincristine on inhibition of proliferation breast cancer cells type MDA-MB231
- Figure 4 Study of the synergistic effect of combinations of 4- (3,4-dichlorophenyl) -1,2,3,4-tetrahydro-naphthalen-1-ylamine cis and vinblastine on inhibition of proliferation breast cancer cells type MDA-MB231
- Figure 5 Evolution during treatment of the median volume of implanted tumors in SCID mice after chronic administration of Cis 4- (3,4-dichloro-phenyl) -1,2,3,4-tetrahydro-naphthalen-1 -ylamine intraperitoneally
- Figure 6 Evolution during treatment of the median volume of implanted tumors in SCID mice after chronic administration of (1S, 4S) 4- (3,4-dichloro-phenyl) -1,2,3,4-tetrahydro 1-naphthalen-1-ylamine intraperitoneally
- Cis 4- (3,4-dichloro-phenyl) -1,2,3,4-tetrahydro-naphthalen-1-ylamine is meant the racemic mixture of the two enantiomers (1S, 4S) 4- (3, 4-dichlorophenyl) -1,2,3,4-tetrahydro-naphthalen-1-ylamine and (1R, 4R) 4- (3,4-dichlorophenyl) -1,2,3,4-tetrahydro- naphthalen-1-ylamine.
- Trans 4- (3,4-dichloro-phenyl) -1,2,3,4-tetrahydro-naphthalen-1-ylamine means the racemic mixture of the two enantiomers (1S, 4R) 4- (3, 4-dichloro-phenyl) -1,2,3,4-tetrahydro-naphthalen-1-ylamine and (1R, 4S) -4- (3,4-dichlorophenyl) -1,2,3,4-tetrahydro- naphthalen-1-ylamine.
- the inventors unexpectedly demonstrate the antitumor effect of 4- (3,4-dichloro-phenyl) -1,2,3,4-tetrahydro-naphthalen-1. ylamine and its enantiomers or any combination of its enantiomers on tumor cell lines of various origin.
- any combination of the enantiomers of 4- (3,4-dichloro-phenyl) -1,2,3,4-tetrahydro-naphthalen-1-ylamine has the property of inhibiting the proliferation of U937 leukemia-like cells. and therefore an antitumor activity
- Example 2 Determination of IC 50 on breast cancer cells MDA-MB231
- Example 3 Determination of IC 50 of (1S, 4S) 4- (3,4-dichloro-phenyl) -1,2,3,4-tetrahydro-naphthalen-1-ylamine on 30 tumor cell lines
- Table 3 groups the IC 50 values of (1S, 4S) -4- (3,4-dichlorophenyl) -1,2,3,4-tetrahydro-naphthalen-1-ylamine on 30 different tumor lines from haematological and solid tumors varied.
- the inventors unexpectedly demonstrate the synergistic antitumor effect of 4- (3,4-dichloro-phenyl) -1,2,3,4-tetrahydronaphthalen-1-ylamine and its enantiomers with alkaloids. of Vinca.
- Example 4 Study of the synergistic effect of combinations of 4- (3,4-dichloro-phenyl) -1,2,3,4-tetrahydro-naphthalen-1-ylamine cis and vincristine on inhibition of proliferation U937 leukemia-like cells
- the final 6 concentrations selected for testing cis 4- (3,4-dichlorophenyl) -1,2,3,4-tetrahydro-naphthalen-1-ylamine were 25, 13, 6.3, 3.1 and 1.6 micromolar ( ⁇ M).
- the final 6 concentrations chosen for testing vincristine were 4000, 1000, 250, 63, and 16 picomolar (pM).
- the antiproliferative activity (percent inhibition of proliferation of 73%) of a combination of vincristine (250 ⁇ M) and cis 4- (3,4-dichlorophenyl) -1,2,3,4-tetrahydro naphthalen-1-ylamine (3.1 ⁇ M) is clearly superior to the effect of the only active agent (21% inhibition for vincristine at 250 ⁇ M).
- the antiproliferative effect observed with this combination is not a simple additivity of the separate effects of the two products given the positive value (+49) calculated for the excess over the additivity "Bliss".
- Example 5 Study of the synergistic effect of combinations of 4- (3,4-dichloro-phenyl) -1,2,3,4-tetrahydro-naphthalen-1-ylamine cis and vinblastine on inhibition of proliferation U937 leukemia-like cells
- the final 6 concentrations selected for testing cis 4- (3,4-dichlorophenyl) -1,2,3,4-tetrahydro-naphthalen-1-ylamine were 25, 13, 6.3, 3.1 and 1.6 micromolar ( ⁇ M).
- the final 6 concentrations chosen to test vinblastine were 4000, 1000, 250, 63, and 16 picomolar (pM).
- Antiproliferative activity (percent inhibition of proliferation 54%) of a combination of vinblastine (250 ⁇ M) and cis 4- (3,4-dichlorophenyl) -1,2,3,4-tetrahydro naphthalen-1-ylamine (3.1 ⁇ M) is clearly superior to the effect of the only active agent (19% inhibition for vinblastine at 250 ⁇ M). Moreover, the antiproliferative effect observed with this combination is not a mere additivity of the separate effects of the two products given the positive value (+31) calculated for the excess over the additivity "Bliss".
- Example 7 Study of the synergistic effect of combinations of (1S, 4S) 4- (3,4-dichloro-phenyl) -1,2,3,4-tetrahydro-naphthalen-1-ylamine and vinblastine on the inhibition of U937 leukemia cell proliferation
- Example 8 Study of the synergistic effect of combinations of 4- (3,4-dichloro-phenyl) -1,2,3,4-tetrahydro-naphthalen-1-ylamine cis and vincristine on inhibition of proliferation breast cancer cells type MDA-MB231
- the final 6 concentrations selected for testing cis 4- (3,4-dichlorophenyl) -1,2,3,4-tetrahydro-naphthalen-1-ylamine were 25, 13, 6.3, 3.1 and 1.6 micromolar ( ⁇ M).
- the final 6 concentrations chosen for testing vincristine were 4000, 1000, 250, 63, and 16 picomolar (pM).
- Incubation of MDA-MB231 cells with different combinations of concentrations of 4- (3,4-dichloro-phenyl) -1,2,3,4-tetrahydro-naphthalen-1-ylamine cis and vincristine reveals the existence of a synergy between the antiproliferative effects of two compounds.
- Example 9 Study of the synergistic effect of combinations of 4- (3,4-dichloro-phenyl) -1,2,3,4-tetrahydro-naphthalen-1-ylamine cis and vinblastine on inhibition of proliferation
- the method described below for evaluating a synergistic effect of combinations of two products on the inhibition of the proliferation of leukemic U937-type cells has been applied with the following compounds:
- Vinblastine The final 6 concentrations chosen to test cis 4- (3,4-dichlorophenyl) -1,2,3,4-tetrahydro-naphthalen-1-ylamine were 25, 13, 6.3, 3, 1 and 1.6 micromolar ( ⁇ M). The final 6 concentrations chosen to test vinblastine were 4000, 1000, 250, 63, and 16 picomolar (pM).
- the inventors unexpectedly demonstrate the antitumor effect of 4- (3,4-dichloro-phenyl) -1,2,3,4-tetrahydro-naphthalen-1-ylamine and its enantiomers administered in the animal carrying a tumor.
- Example 10 Study of the antitumor effect in the mice of 4- (3,4-dichlorophenyl) -1,2,3,4-tetrahydro-naphthalen-1-ylamine after chronic administration by intrapertemal route
- the inventors tested the antitumor effect in mice of Cis 4- (3,4-dichloro-phenyl) -1,2,3,4-tetrahydro-naphthalen-1-ylamine, by applying the method described below.
- the inventors administered Cis 4- (3,4-dichlorophenyl) -1,2,3,4-tetrahydronaphthalen-1-ylamine to mice which had previously been grafted with tumor cells. . They compared tumor growth in animals treated with Cis 4- (3,4-dichloro-phenyl) -1,2,3,4-tetrahydro-naphthalen-1-ylamine with that of tumors in non-controlled animals.
- Cis 4- (3,4-dichloro-phenyl) -1,2,3,4-tetrahydro-naphthalen-1-ylamine significantly slows tumor growth in the mice thus treated.
- the inventors analyzed the average tumor size in subcutaneous tumor-bearing mice treated with Cis 4- (3,4-dichlorophenyl) -1,2,3,4-tetrahydro-naphthalen-1-ylamine and compared it to that of the "control" mice bearing these tumors and treated with the vehicle of the test substance only.
- Figure 5 represents the average volume of subcutaneous tumors carried by mice (in mm3) treated with Cis 4- (3,4-dichloro-phenyl) -1,2,3,4-tetrahydro-naphthalen-1-ylamine as a function of time elapsed (in days) since the first day of treatment (50 mg / kg intraperitoneally), compared to the average volume of tumors carried by vehicle-treated mice.
- the tumor volume of the mice treated with the compound of the invention is much lower than that of the untreated mice, which reveals a clear anti-tumor effect of Cis 4- (3,4-dichlorophenyl) -1, 2,3,4-Tetrahydronaphthalen-1-ylamine.
- Example 11 Study of the anti-tumor effect in mice of (1S, 4S) 4- (3,4-dichloro-phenyl) -1,2,3,4-tetrahydro-naphthalen-1-ylamine after chronic administration intraperitoneally
- the inventors tested the anti-tumor effect in mice of (1S, 4S) 4- (3,4-dichloro-phenyl) -1,2,3,4-tetrahydro-naphthalene-1 ylamine, using the method described below.
- the inventors administered (1S, 4S) 4- (3,4-dichloro-phenyl) -1,2,3,4-tetrahydro-naphthalen-1-ylamine to mice which had previously been grafted tumor cells.
- the inventors analyzed the average tumor size in subcutaneous tumor-bearing mice and treated with (1S, 4S) 4- (3,4-dichlorophenyl) -1,2,3,4-tetrahydro-naphthalene. l-ylamine and compared it to that of "control" mice bearing these tumors and treated with the vehicle of the test substance only.
- Figure 6 shows the average volume of subcutaneous tumors carried by mice (in mm3) treated with (1S, 4S) 4- (3,4-dichloro-phenyl) -1,2,3,4-tetrahydro-naphthalene.
- -l-ylamine as a function of the time elapsed (in days) since the first day of treatment (15 mg / kg twice daily intraperitoneally), compared to the average volume of tumors carried by vehicle-treated mice.
- Example 12 Study of pharmacokinetic parameters (half-life, bioavailability) of (1S, 4S) 4- (3,4-dichloro-phenyl) -1,2,3,4-tetrahydronaphthalen-1-ylamine in mice Pharmacokinetic studies were performed with (1S, 4S) -4-
- Pathway Rate Tl / 2 Cl AUCAU AUC (mg / kg) (min) (inL / inin / kg) (min * ng / mL) (min * ng / mL)
- the inventors tested the anti-tumor effect in mice of (1S, 4S) 4- (3,4-dichloro-phenyl) -1,2,3,4-tetrahydro-naphthalen-1-ylamine. By applying the method described below. In order to test this effect, the inventors administered (1S, 4S) 4- (3,4-dichloro-phenyl) -1,2,3,4-tetrahydro-naphthalen-1-ylamine to mice which had previously been grafted tumor cells.
- Table 5 reports the median volumes (in mm 3 ) of subcutaneous tumors carried by SCID mice treated with (1S-4S) -4- (3,4-dichlorophenyl) -1,2,3,4- tetrahydro-naphthalen-1-ylamine as a function of elapsed time (in days) since the first day of treatment (80 mg / kg daily and oral) and median volumes of tumors carried by vehicle-treated mice on the same days. Days 5 and 18 correspond respectively to day after the first day of treatment.
- Table 5 shows the median volumes of tumors implanted in SCID mice after chronic administration of (1S, 4S) 4- (3,4-dichloro-phenyl) -1,2,3,4-tetrahydro- naphthalen-l-ylamine orally Table 5
- the median volume of tumors carried by the mice treated with the compound of the invention is significantly less (by almost half) the median volume of tumors carried by the vehicle-treated mice.
- (1S, 4S) -4- (3,4-dichloro-phenyl) -1,2,3,4-tetrahydronaphthalen-1-ylamine administered orally has an anti-tumor effect in animal.
- Example 14 Study of the cerebral penetration of (1S, 4S) 4- (3,4-dichlorophenyl) -1,2,3,4-tetrahydro-naphthalen-1-ylamine in mice
- 1,2,3,4-Tetrahydro-naphthalen-1-ylamine is active in vitro on tumor lines derived from glioblastomas.
- the experiments reported below demonstrate that (1S, 4S) -4- (3,4-dichloro-phenyl) -1,2,3,4-tetrahydro-naphthalen-1-ylamine possesses the ability to cross the blood-brain barrier significantly, which is a major advantage of this compound for the treatment of brain tumors.
- (1S, 4S) -4- (3,4-Dichloro-phenyl) -1,2,3,4-tetrahydro-naphthalen-1-ylamine was injected intravenously into a group of CD1 mice, at a rate of 1 mg / kg.
- mice (1S, 4S) 4- (3,4-dichloro-phenyl) -1,2,3,4-tetrahydro-naphthalen-1-ylamine brain penetration are reported in the literature. Table 6 below.
- (3,4-dichloro-phenyl) -1,2,3,4-tetrahydro-naphthalen-1-ylamine in the brain are more important than in plasma and the ratio of concentration of this compound between brain and blood increases with time (over the interval analyzed) thus showing the brain's capacity for accumulation.
- test compound is dissolved in DMSO (100%) at a concentration of 1.10 -2 M (stock solution) and then 8 samples of 8 different concentrations are prepared by successive dilution with the complete cell culture medium (RPMI 1640 Cambrex + 10% FBS + 1% L-Glutamine + 40 ⁇ g / ml Gentamycin) For each sample, the dilution volume is adjusted to obtain an equal concentration at twice the final selected concentration C x.
- complete cell culture medium RPMI 1640 Cambrex + 10% FBS + 1% L-Glutamine + 40 ⁇ g / ml Gentamycin
- a 96-well white non-transparent plate (fluoronunc 96F Nunclon Delta)
- 100 ⁇ l of a suspension of U937 cells at a concentration of 2.5 ⁇ 10 4 cells / ml in RPMI1640 Cambrex medium + 10% FBS + 1% L-Glutamine + 40 ⁇ g / ml of Gentamycin are deposited in each well, ie 2500 cells per well.
- 100 ⁇ L of a 2 x C x sample are added (one sample per well) and the medium is homogenized.
- the quantification of the viability of the cells in culture is carried out by measuring the levels of ATP using the test.
- Control C x average luminescence measurements of three wells of the corresponding control sample • Lum.
- (white) average luminescence measurements of eight wells comprising only 200 ⁇ l of cell culture medium (RPMI 1640 Cambrex + 10% FBS + 1% L-Glutamine + 40 ⁇ g / ml Gentamycin)
- IC 50 is the concentration of the compound required to achieve 50% inhibition of cell proliferation; these values are calculated with XLfit 3 software (ID Business Solutions Ltd., UK) from semi-logarithmic curves.
- test compound is dissolved in DMSO (100%) at a concentration of 1.10 -2 M (stock solution) and then 8 samples of 8 different concentrations are prepared by successive dilution with the complete cell culture medium (E-MEM Cambrex + 10% FBS, + 1% non-essential amino acids + 1% Napyruvate + 1% L-Glutamine + 40 ⁇ g / ml Gentamycin)
- the dilution volume is adjusted to obtain a concentration equal to twice the final concentration C x chosen, for example 1.1 O ⁇ M, 5.10 " 5M, 2.5.10 ⁇ 5M, 1.3.10 " 5M, 6.3.10 " 6M, 3.1.10 " 6M, 1, 6.10 ⁇ 6M and 7.8.10 ⁇ 7M is a standard range of 8 final concentrations.
- control samples are prepared by diluting a solution of DMSO (100%) with even the cell culture medium (E-MEM Cambrex + 10% FBS, + 1% non-essential amino acids + 1% Napyruvate + 1% L-Glutamine + 40 ⁇ g / ml Gentamycin), the dilution volumes chosen being strictly identical to those used for the preparation of the samples of the test compound.
- E-MEM Cambrex + 10% FBS, + 1% non-essential amino acids + 1% Napyruvate + 1% L-Glutamine + 40 ⁇ g / ml Gentamycin the dilution volumes chosen being strictly identical to those used for the preparation of the samples of the test compound.
- a 96-well white non-transparent plate (fluoronunc 96F Nunclon Delta)
- 100 ⁇ l of a suspension of MDA-MB231 cells at a concentration of 1.25 ⁇ 10 4 cells / ml in an E-MEM Cambrex medium + 10% FBS, + 1% of non-essential amino acids + 1% Napyruvate + 1% L-Glutamine + 40 ⁇ g / ml of Gentamycin are deposited in each well, ie 2500 cells per well.
- 100 ⁇ L of a 2 x C x sample are added (one sample per well) and the medium is homogenized. After 144h of incubation at 37 ° C.
- the quantification of the viability of the cells in culture is carried out by measuring the levels of ATP using the test.
- CellTiter-Glo TM Luminescent Assay System supplied by Promega Corporation according to the supplier's instructions. The luminescence in each well is measured using a counter, VICTOR 2 1420 (Wallac, PerkinElmer, Courtaboeuf, France).
- Lum. (white) average luminescence measurements of eight wells comprising only 200 ⁇ L of cell culture medium (E-MEM Cambrex + 10% FBS, + 1% non-essential amino acids + 1%
- IC 50 is the concentration of the compound required to achieve 50% inhibition of cell proliferation; these values are calculated with XLfit 3 software (ID Business Solutions Ltd., UK) from semi-logarithmic curves.
- each product is dissolved in DMSO (100%) at a concentration of 1.10 -2 M (stock solution) then, for each product, 6 samples of 6 different concentrations are prepared by successive dilution with the complete cell culture medium (RPMI 1640 Cambrex + 10% FBS + 1% L-Glutamine + 40 ⁇ g / ml Gentamycin) For each sample, the dilution volume is adjusted to obtain a concentration equal to four times the final concentration chosen.
- the complete cell culture medium RPMI 1640 Cambrex + 10% FBS + 1% L-Glutamine + 40 ⁇ g / ml Gentamycin
- a cell suspension at 2.5 ⁇ 10 4 cells / ml is prepared in complete medium, and 36 ⁇ 100 ⁇ l of this solution (ie 2500 cells / well) are distributed in 36 wells of a 96-well plate, white and non-transparent (fluoronunc 96F Nunclon). Delta).
- 36 ⁇ 100 ⁇ l of this solution ie 2500 cells / well
- 50 ⁇ l of a sample of product A concentrated four times and 50 ⁇ l of a sample of product B concentrated four times to obtain a final volume of 200 ⁇ l.
- Each sample of product A (6 concentrations Al, A2, A3, A4, A5, A6) is combined with each sample of product B (6 concentrations B1, B2, B3, B4, B5, B6).
- Concentrations A6 and B6 correspond to a zero concentration of product A and product B respectively.
- the A6 / B6 combination therefore corresponds to a drug-free well and DMSO, which serves as a cell growth reference.
- the quantification of the viability of the cells in culture is carried out by measuring the levels of ATP using the test.
- CellTiter-Glo TM Luminescent Assay System supplied by Promega Corporation according to the supplier's instructions. The luminescence in each well is measured using a counter, VICTOR 2 1420 (Wallac, PerkinElmer, Courtaboeuf, France).
- Lum. (white) average of 6-well luminescence measurements comprising only 200 ⁇ l of cell culture medium (RPMI 1640 Cambrex + 10% FBS + 1% L-Glutamine + 40 ⁇ g / ml of
- the method used for MDA-MB231 breast cancer cells is similar to that used for U937 leukemia-type cells with the exception of the concentration of the cell suspension (1.25 ⁇ 10 4 cells / ml for MDA-MB231 instead 2.5 ⁇ 10 4 cells / ml for U937).
- the composition of the complete medium is also modified: E-MEM Cambrex + 10% FBS, + 1% non-essential amino acids + 1% Napyruvate + 1% L-Glutamine + 40 ⁇ g / ml Gentamycin.
- the cells were incubated in a final volume of 200 ⁇ l of a culture medium supplemented with 10% fetal bovine serum containing the test compound at 37 ° C. under an atmosphere containing 5% CO 2 .
- Tumor cells were incubated for 96 hours with final concentrations of the test compound (range of 1 x 10-4 to 4 x 10- 10 M). Each final concentration was assayed in quadriplicate.
- the vehicle of the tested compound At the end of the treatment period, the antiproliferative activity was evaluated by a colorimetric test using the tetrazolium salt MTS (3- (4,5-dimethylthiazol-2-yl) -5- (3-carboxymethoxy phenyl) -2- (4-sulfophenyl) -2H-tetrazolium, Baltrop JA et al., Bioorg Med Chem, Lett, 1991, 1: 611-614).
- IC 50 is the concentration of the compound required to achieve 50% inhibition of cell proliferation; these values are calculated with XLfit 3 software (ID Business Solutions Ltd., UK) from semi-logarithmic curves.
- U937 viable cells in a volume of 200 .mu.l of RPMI culture medium are injected subcutaneously into the right flank of a SCID mouse.
- the injection of the cells is carried out 24 hours after the complete irradiation of the body with a ⁇ source (1.8 Gy, Co 60 , INRA BRETENIERE, Dijon,
- Treatment plan Treatment is initiated when the tumors have reached an average volume of about 50 mm 3 .
- the mice are randomly assigned to groups of 10 mice so that the mean tumor volume of each group is not statistically different from the other groups (variance analysis).
- Tween-20 (Ref P7949, Sigma). The suspensions are then diluted in water to achieve the desired concentration of the test compound and a final Tween-20 concentration of 1% (v / v).
- IP intraperitoneal
- the mice received repeated intraperitoneal (IP) injections of the vehicle (Tween-1% (v / v) or the test compound at the dose and according to the chosen treatment plan (once daily or twice daily for 30 minutes).
- IP intraperitoneal
- the products and the vehicle are administered by gavage.
- tumor volume (width 2 x length) / 2.
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Emergency Medicine (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Description
Claims
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR0507480A FR2888506A1 (fr) | 2005-07-12 | 2005-07-12 | Utilisation de la 4-(3,4-dichloro-phenyl)-1,2,3,4- tetrahydro-naphtalen-1-ylamine pour le traitement du cancer |
PCT/EP2006/064155 WO2007006797A1 (fr) | 2005-07-12 | 2006-07-12 | Utilisation de la 4-(3,4-dichloro-phenyl)-1,2,3,4-tetrahydro-naphtalen-1-ylamine pour le traitement du cancer |
Publications (1)
Publication Number | Publication Date |
---|---|
EP1904045A1 true EP1904045A1 (fr) | 2008-04-02 |
Family
ID=35925210
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP06777730A Withdrawn EP1904045A1 (fr) | 2005-07-12 | 2006-07-12 | Utilisation de la 4-(3,4-dichloro-phenyl)-1,2,3,4-tetrahydro-naphtalen-1-ylamine pour le traitement du cancer |
Country Status (14)
Country | Link |
---|---|
EP (1) | EP1904045A1 (fr) |
JP (1) | JP2009501193A (fr) |
KR (1) | KR20080031748A (fr) |
CN (1) | CN101222917A (fr) |
AU (1) | AU2006268657A1 (fr) |
CA (1) | CA2614696A1 (fr) |
FR (1) | FR2888506A1 (fr) |
IL (1) | IL188685A0 (fr) |
MA (1) | MA29729B1 (fr) |
NO (1) | NO20080722L (fr) |
RU (1) | RU2008101268A (fr) |
TN (1) | TNSN08010A1 (fr) |
WO (1) | WO2007006797A1 (fr) |
ZA (1) | ZA200800500B (fr) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2643602T3 (es) * | 2006-03-31 | 2017-11-23 | Sunovion Pharmaceuticals Inc. | Aminas y quirales |
FR2909283A1 (fr) * | 2006-11-30 | 2008-06-06 | Cerep Sa | Produit de combinaison contenant de la n-desmethylsertraline, ou un de ses sels, et un agent antineoplasique pour le traitement du cancer |
FR3071726B1 (fr) * | 2017-09-29 | 2020-09-04 | Univ Paris Sud | Agents inhibant la proteine tctp pour le traitement de maladies proliferatives et de maladies infectieuses |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2265695A (en) * | 1995-01-17 | 1996-08-07 | Pfizer Inc. | The use of sertraline to treat cancer patients |
US20050013853A1 (en) * | 2000-11-29 | 2005-01-20 | Irit Gil-Ad | Anti-proliferative drugs |
JP2007503396A (ja) * | 2003-08-22 | 2007-02-22 | ファルマシア コーポレイション | 新形成の治療のためのシクロオキシゲナーゼ−2選択的阻害剤及びセロトニン−調節剤の組成物 |
-
2005
- 2005-07-12 ZA ZA200800500A patent/ZA200800500B/xx unknown
- 2005-07-12 FR FR0507480A patent/FR2888506A1/fr active Pending
-
2006
- 2006-07-12 CA CA002614696A patent/CA2614696A1/fr not_active Abandoned
- 2006-07-12 EP EP06777730A patent/EP1904045A1/fr not_active Withdrawn
- 2006-07-12 KR KR1020087001702A patent/KR20080031748A/ko not_active Application Discontinuation
- 2006-07-12 AU AU2006268657A patent/AU2006268657A1/en not_active Abandoned
- 2006-07-12 WO PCT/EP2006/064155 patent/WO2007006797A1/fr active Application Filing
- 2006-07-12 JP JP2008520878A patent/JP2009501193A/ja active Pending
- 2006-07-12 CN CNA2006800257620A patent/CN101222917A/zh active Pending
- 2006-07-12 RU RU2008101268/15A patent/RU2008101268A/ru unknown
-
2008
- 2008-01-09 IL IL188685A patent/IL188685A0/en unknown
- 2008-01-11 TN TNP2008000010A patent/TNSN08010A1/fr unknown
- 2008-02-01 MA MA30615A patent/MA29729B1/fr unknown
- 2008-02-08 NO NO20080722A patent/NO20080722L/no not_active Application Discontinuation
Non-Patent Citations (1)
Title |
---|
See references of WO2007006797A1 * |
Also Published As
Publication number | Publication date |
---|---|
MA29729B1 (fr) | 2008-09-01 |
RU2008101268A (ru) | 2009-08-20 |
FR2888506A1 (fr) | 2007-01-19 |
JP2009501193A (ja) | 2009-01-15 |
WO2007006797A8 (fr) | 2007-04-19 |
IL188685A0 (en) | 2008-12-29 |
CN101222917A (zh) | 2008-07-16 |
WO2007006797A1 (fr) | 2007-01-18 |
TNSN08010A1 (fr) | 2009-07-14 |
ZA200800500B (en) | 2009-04-29 |
CA2614696A1 (fr) | 2007-01-18 |
NO20080722L (no) | 2008-04-04 |
KR20080031748A (ko) | 2008-04-10 |
AU2006268657A1 (en) | 2007-01-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Kumar et al. | Pharmacological actions and therapeutic uses of cannabis and cannabinoids | |
EP1883452B1 (fr) | Composition pharmaceutique comprenant un agent antiparasitaire et un actif choisi parmi le thymol, l'eugénol, et le carvacrol | |
FR2788982A1 (fr) | Compositions pharmaceutiques contenant de la nicotine et leur application dans le sevrage tabagique | |
JP2002520273A (ja) | 抗うつ効果を有する治療薬 | |
JP2010540587A (ja) | 炎症性疾患治療用非向精神性カンナビノイド含有組成物 | |
KR20100016385A (ko) | 뇌종양 치료방법 | |
JP2008540405A (ja) | 酢酸エスリカルバゼピン及び使用方法 | |
AU2009313906A1 (en) | Treatment of proteinopathies using a farnesyl transferase inhibitor | |
Pena-Dos-Santos et al. | Activation of peripheral κ/δ opioid receptors mediates 15-deoxy-Δ12, 14-prostaglandin J2 induced-antinociception in rat temporomandibular joint | |
EP1365763A1 (fr) | Combinaisons d'inhibiteurs de la farnesyle proteine transferase avec agents anti-oestrogene | |
Barreto da Silva et al. | Antihypertensive effect of carvacrol is improved after incorporation in β‐cyclodextrin as a drug delivery system | |
EP1904045A1 (fr) | Utilisation de la 4-(3,4-dichloro-phenyl)-1,2,3,4-tetrahydro-naphtalen-1-ylamine pour le traitement du cancer | |
KR20090110909A (ko) | 에스리카르바제핀의 치료적 용도 | |
Merheb et al. | Drug-induced peripheral neuropathy: diagnosis and management | |
KR20210010524A (ko) | 샘낭암종을 치료하기 위한 비스플루오로알킬-1,4-벤조디아제피논 화합물을 포함하는 조성물 | |
JP2009503072A (ja) | 退形成性神経膠腫に対する補助的化学療法 | |
Kino et al. | Involvement of supraspinal imidazoline receptors and descending monoaminergic pathways in tizanidine-induced inhibition of rat spinal reflexes | |
EP2214789A2 (fr) | Nouvelle composition pour traiter les effets secondaires des traitements anticancereux | |
JP2024523485A (ja) | 少なくとも1種類のセロトニン再取り込み阻害剤及び少なくとも1種の塩化カリウム共輸送体2型の刺激剤を含む組み合せ、並びにその医学的使用 | |
JP6875279B2 (ja) | 癌またはその転移の予防または治療剤 | |
WO2007006799A1 (fr) | Utilisation de la sertraline en combinaison avec un alcaloïde pour le traitement du cancer | |
EP4329752A1 (fr) | Cardioprotection par induction d'autophagie et reprogrammation metabolique | |
WO2008065193A1 (fr) | Produit de combinaison contenant de la n-desmethylsertraline, ou un de ses sels, et un agent antineoplasique pour le traitement du cancer | |
MX2008000698A (en) | Use of 4-(3,4-dichloro-phenyl)-1,2,3,4-tetrahydro-naphtalen-1-ylamine for treating cancer | |
WO2023133414A2 (fr) | Élimination sélective de cellules sénescentes par induction de la ferroptose |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20080207 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR |
|
DAX | Request for extension of the european patent (deleted) | ||
DAX | Request for extension of the european patent (deleted) | ||
RIN1 | Information on inventor provided before grant (corrected) |
Inventor name: AMSON, ROBERT Inventor name: TUIJNDER, MARIUS Inventor name: REVAH, FREDERIC Inventor name: BALAVOINE, FABRICE Inventor name: TELERMAN, ADAM |
|
REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 1114788 Country of ref document: HK |
|
17Q | First examination report despatched |
Effective date: 20090424 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
18D | Application deemed to be withdrawn |
Effective date: 20090905 |
|
REG | Reference to a national code |
Ref country code: HK Ref legal event code: WD Ref document number: 1114788 Country of ref document: HK |